Objectives: To describe allergic asthma and allergic rhinitis pathophysiology and review the pharmacologic, pharmacokinetic, pharmacodynamic, efficacy, and safety data for omalizumab. Methods ...

After four months of monthly or bimonthly omalizumab injections, two-thirds of the 118 participants receiving the drug safely ate small amounts of their allergy-triggering foods. Notably ...

Omalizumab is generally well tolerated in adults and children with allergic asthma. Adverse events most commonly observed are injection-site reaction, viral infection, upper-respiratory-tract ...

Omalizumab has been shown to improve participants ... The drug is delivered as an injection every two to four weeks and targets a specific antibody called IgE. IgE - like other human antibodies ...

Xolair (omalizumab) generated revenues of more ... which is available in markets in the US and EU as a subcutaneous injection lasting a few minutes, instead of a lengthy infusion.